Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas

Experimental Dermatology

Volumn 20, Issue 4, 2011, Pages 331-335

  Kaune, Kjell M ^a   Neumann, Christine ^a   Hallermann, Christian ^a,b   Haller, Florian ^a,d   Schön, Michael P ^a   Middel, Peter ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Fachklinik Hornheide ^*  (Germany)

^c Clinical Center of Kassel   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CDKN2A; Fluorescence in situ hybridization (FISH); p14; p16; p53; Primary cutaneous B cell lymphoma; Rb

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P14; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MARGINAL ZONE LYMPHOMA; MUTATION; PHOSPHORYLATION; PRIMARY CUTANEOUS DIFFUSE LARGE B CELL LYMPHOMA LEG TYPE; PRIMARY CUTANEOUS FOLLICLE CENTER LYMPHOMA; PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA; PROTEIN EXPRESSION; RETINOBLASTOMA; TRISOMY; TRISOMY 9;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P16; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHOSPHORYLATION; SEQUENCE DELETION; SKIN NEOPLASMS; TRISOMY; TUMOR SUPPRESSOR PROTEIN P14ARF; YOUNG ADULT;

EID: 79952732504     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01226.x     Document Type: Article

References (22)

1. Willemze R, Jaffe E S, Burg G et al. Blood 2005: 105: 3768-3785.
2. Mao X, Lillington D, Child F et al. Genes Chromosom Cancer 2002: 35: 144-155.
3. Hallermann C, Kaune K M, Siebert R et al. J Invest Dermatol 2004: 122: 1495-1502.
4. Hallermann C, Kaune K M, Gesk S et al. J Invest Dermatol 2004: 123: 213-219.
5. Giménez S, Costa C, Espinet B et al. Exp Dermatol 2005: 14: 883-890.
6. Dijkman R, Tensen C P, Jordanova E S et al. J Clin Oncol 2006: 24: 296-305.
7. Belaud-Rotureau M A, Marietta V, Vergier B et al. Virchows Arch 2008: 452: 607-620.
8. Senff N J, Zoutman W H, Vermeer M H et al. J Invest Dermatol 2009: 129: 1149-1155.
9. Gil J, Peters G. Nat Rev Mol Cell Biol 2006: 7: 667-677.
10. Goodrich D W. Oncogene 2006: 25: 5233-5243.
11. Polager S, Ginsberg D. Nat Rev Cancer 2009: 9: 738-748.
12. Koduru P R, Raju K, Vadmal V et al. Blood 1997: 90: 4078-4091.
13. Braun-Falco M, Schempp W, Weyers W. Exp Dermatol 2009: 18: 12-23.
14. Martin-Subero J I, Gesk S, Harder L et al. Anticancer Res 2003: 23: 1139-1148.
15. Wiesner T, Streubel B, Huber D et al. Am J Surg Pathol 2005: 29: 666-673.
16. Herman J G, Civin C I, Issa J P et al. Cancer Res 1997: 57: 837-841.
17. Baur A S, Shaw P, Burri N et al. Blood 1999: 94: 1773-1781.
18. Child F J, Scarisbrick J J, Calonje E et al. J Invest Dermatol 2002: 118: 941-948.
19. Grønbaek K, Møller P H, Nedergaard T et al. Br J Dermatol 2000: 142: 913-923.
20. Takino H, Li C, Hu S et al. Mod Pathol 2008: 21: 1517-1526.
21. Beylot-Barry M, Vergier B, DeMascarel A et al. Arch Dermatol 1995: 131: 1019-1024.
22. Mitelman F (ed.). ISCN1995. An International System for Human Genetic Nomenclature. Basel: S. Karger, 1995.